Balázs Győrffy - Selected Publications#

1. Patten DK, Corleone G, GYŐRFFY B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L. Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nat Med. 2018 Sep;24(9):1469-1480. AS SECOND AUTHOR. IMPACT FACTOR 32.6.

2. de Barrios O, GYŐRFFY B, Fernández-Aceñero MJ, Sánchez-Tilló E, Sánchez-Moral L, Siles L, Esteve-Arenys A, Roué G, Casal JI, Darling DS, Castells A, Postigo A. ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1. Gut. 2017 Apr;66(4):666-682. AS SECOND AUTHOR. IMPACT FACTOR 17.0.

3. Menyhárt O, Harami-Papp H, Sukumar S, Schäfer R, Magnani L, de Barrios O, GYŐRFFY B*. Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochim Biophys Acta. 2016 Dec;1866(2):300-319. AS LAST AUTHOR. THIS PAPER WAS THE MOST DOWNLOADED PAPER OF BBA IN 2017 AND 2018 (ACCORDING TO THE JOURNAL HOMEPAGE).

4. Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, GYŐRFFY B*. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016 Dec;160(3):439-446. AS LAST AUTHOR. THIS PAPER WAS CITED 140X.

5. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A, GYŐRFFY B*. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016 Aug 2;7(31):49322-49333. AS LAST AUTHOR. THIS PAPER WAS CITED 300X.

6. *GYŐRFFY B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2015 Dec;17(1):514. AS FIRST AUTHOR. THIS PAPER WAS CITED 150X.

7. *GYŐRFFY B, Surowiak P, Budczies J, Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013 Dec 18;8(12):e82241. AS FIRST AUTHOR. THIS PAPER WAS CITED 600X.

8. Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, GYŐRFFY B*, Lupien M*. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1490-9. AS CORRESPONDING AUTHOR. THIS PAPER WAS CITED 100X.

9. *GYŐRFFY B, Lánczky A, Szállási Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data of 1287 patients, Endocrine-Related Cancer. 2012 Apr 10;19(2):197-208. AS FIRST AUTHOR. THIS PAPER WAS CITED 320X.

10. *GYŐRFFY B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients, Breast Cancer Res Treatment, 2010 Oct;123(3):725-31. AS FIRST AUTHOR. THIS PAPER WAS CITED 1100X.